ENCell KRX:456070KOSDAQ
이엔셀 · Korean news coverage and regulatory filings, organized.
Articles, 24h7
Articles, 7 days7
DART filings, 7 days0
Articles tracked7since Sep 11
In Q2 2026, ENCell reported revenue of ₩868m, down 26.3% year on year, and an operating loss of ₩4.7bn. ENCell (이엔셀) appeared in 7 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 7 articles.
ENCell quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩868m | -26.3% | −₩4.7bn | −₩7.2bn |
| Q1 2026 | ₩309m | -71.8% | −₩4.9bn | −₩5.3bn |
| Q4 2025 derived | ₩1.4bn | -31.1% | −₩4.9bn | −₩3.5bn |
| Q3 2025 | ₩1.5bn | +5.2% | −₩3.7bn | −₩3.6bn |
| Q2 2025 | ₩1.2bn | -36.6% | −₩4.5bn | −₩4.3bn |
| Q1 2025 | ₩1.1bn | -38.9% | −₩4.8bn | −₩4.6bn |
| Q4 2024 derived | ₩2.1bn | -62.7% | −₩5.5bn | −₩5.2bn |
| Q3 2024 | ₩1.5bn | -10.5% | −₩4.2bn | −₩4.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
ENCell top stories 2 weeks, by number of outlets
- 1
- 2
- 3
Latest ENCell news Korean headlines
-
이엔셀, 日 줄기세포 재생의료 시장 본격 진출…JK JAPAN과 사업 협력
4 more on this story · 3 outlets
- 이엔셀, 日 줄기세포 재생의료 시장 본격 진출이데일리 · 10:17
- 이엔셀, 日 줄기세포 재생의료 시장 본격 진출이데일리증권 · 10:17
- 이엔셀, 日 줄기세포 재생의료 시장 본격 진출이데일리 · 10:19
- 이엔셀, 日 JK JAPAN과 맞손…줄기세포 재생·미용의료 시장 진출이투데이 · 10:20